PHA News
is an e-mail newsletter from the Pulmonary Hypertension Association covering
PH related topics.
First of all, I would like to wish each and everyone a Happy New Year.
It has been quite a year for us. PHA News now goes out to more than
4,000 people. 2004 will be exciting. We will be having our 6th International
Conference in June in Miami. There are many more treatments on the horizon.
PHA is growing by leaps and bounds with members as well as services
to our members.
Encysive
shares rise 18 pct after upbeat analyst note
Shares of Encysive Pharmaceuticals Inc.rose nearly 18 percent on
Tuesday after SG Cowen initiated coverage of the biotechnology company's
stock by rating it "outperform," its second-highest rating. In a
research note, SG Cowen analyst Phil Nadeau wrote that Encysive
had "one of biotech's most promising emerging product opportunities
for 2004." Encysive is expected to complete pivotal late stage clinical
trials of its experimental treatment called Sitaxsentan for the
often fatal condition pulmonary hypertension in the second half
of 2004.
AstraZeneca
Submits New Drug Application (NDA) for Investigational EXANTA(R) (ximelagatran)
as First New Oral Anticoagulant in Over 50 Years
EXANTA is the first oral anticoagulant
to reach late-stage clinical trials since the development of warfarin
more than 50 years ago. The intended mechanism of action of EXANTA is
to inhibit the activity of an enzyme called thrombin, which is critical
to the final step in the formation of blood clots. Clinical studies with
EXANTA utilize a fixed dose without coagulation monitoring.
Doctor explains concerns of cluster of pulmonary disease
Dr. Raul Menzoda-Ayala, a pulmonologist, said he is trying to educate the public about sarcoidosis, a disease he has treated in about 40 patients from the area. He also discussed primary pulmonary hypertension. Mendoza-Ayala said the cause of sarcoidosis is unknown, but that certain areas of the country tend to have clusters of patients. There must be something in our environment and in our genes that's causing this response," he said.
Pulmonary
Hypertension - A Patient's Survival Guide The premiere information
resource for people dealing with PH
The author, a PH patient herself,
knows what it is like to live with the disease. She talked to many
other patients, doctors, and researchers while writing the Survival
Guide. Dr. Bruce Brundage, a physician with a deep knowledge of
PH, edited the book for accuracy.
This is an informational piece presented by National Heart Lung and Blood Institute. It discusses the incidence of PPH and what may be the cause of it. It also discusses the course of the disease, how it is diagnosed and the treatments that are being used for PPH. Please note: This was printed in the early 1990's before many of the oral treatments were available.
The
information provided on the PHA website is provided for general information
only. It is not intended as legal, medical or other professional
advice, and should not be relied upon as a substitute for consultations
with qualified professionals who are familiar with your individual
needs.
